Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

September 1, 2019

Study Completion Date

July 1, 2020

Conditions
Hemangioma Liver
Interventions
PROCEDURE

sclerotherapy arm

The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.

Trial Locations (1)

1419733141

Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT03649113 - Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin | Biotech Hunter | Biotech Hunter